Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis

Clinical and Experimental Immunology

Volumn 188, Issue 1, 2017, Pages 79-85

  Koutsonikoli, Artemis ^a   Trachana, M ^a   Farmaki, E ^a   Tzimouli, V ^a   Pratsidou Gertsi, P ^a   Printza, N ^a   Garyphallos, A ^a   Galanopoulou, V ^b   Kanakoudi Tsakalidou, F ^a   Papachristou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Autoantibodies; Biomarkers; Paediatric lupus nephritis

Indexed keywords

COMPLEMENT COMPONENT C1Q; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; NUCLEOSOME ANTIBODY; ANTIGLOMERULAR BASEMENT MEMBRANE ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLEDAI; ADULT; BLOOD; CASE CONTROL STUDY; CHILD; IMMUNOLOGY; LUPUS NEPHRITIS; ONSET AGE; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1Q; FEMALE; HMGB1 PROTEIN; HUMANS; LUPUS NEPHRITIS; MALE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85010223538     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12913     Document Type: Article

References (39)

1. Weiss JE. Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody. Pediatr Rev 2012; 33:62-73.
2. Papadimitraki E, Isenberg D. Childhood-and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 2009; 50:391-403.
3. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011; 20:1345-55.
4. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010; 2010:638413.
5. Tang S, Lui SL, Lai KN. Pathogenesis of lupus nephritis: an update. Nephrology (Carlton) 2005; 10:174-9.
6. Mortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol 2008; 172:275-83.
7. Trouw LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114:679-88.
8. Golan MD, Burger R, Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol 1982; 129:445-7.
9. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol 2009; 183:3512-21.
10. Ho J, Gibson IW, Zacharias J, Fervenza F, Colon S, Borza DB. Antigenic heterogeneity of IgA anti-GBM disease: new renal targets of IgA autoantibodies. Am J Kidney Dis 2008; 52:761-5.
11. Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011; 270: 309-18.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
13. Petri M, Orbai AM, Alarcón GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677-86.
14. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241-50.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
16. Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxf) 2011; 50:982-8.
17. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012; 12:97-106.
18. Campos LM, Kiss MH, Scheinberg MA, Mangueira CL, Silva CA. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus 2006; 15:496-500.
19. Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun 2006; 27:119-24.
20. El Sherbini HM, El Garf AK, El Din Mahmoud SS. Human leukocyte antigen and autoantibodies association with juvenile systemic lupus erythematosus. Egypt J Immunol 2009; 16:107-14.
21. Jesus AA, Campos LM, Liphaus BL et al. Anti-C1q, anti-chromatin/ nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients. Rev Bras Reumatol 2012; 52:976-81.
22. Keusseyan SP, da Silva NP, Hilário MO, Okuda EM, Terreri MT, Andrade LE. Diagnostic performance and clinical associations of antibodies to the chromatin antigenic system in juvenile systemic lupus erythematosus. Rev Bras Reumatol 2012; 52:695-712.
23. Massa M, De Benedetti F, Pignatti P et al. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:219-25.
24. Kozyro I, Perahud I, Sadallah S et al. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics 2006; 117:1663-8.
25. Wu FQ, Zhao Q, Cui XD, Zhang W. C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus. Rheumatol Int 2011; 31:501-5.
26. Edelbauer M, Kshirsagar S, Riedl M et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26:401-10.
27. Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL. Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with diseaseassociated manifestations. Semin Arthritis Rheum 2012; 41:840-8.
28. Abdel Kader MS, Abd Elaziz MM, Ahmed DH. Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE. Expert Opin Med Diagn 2012; 6:489-98.
29. Mosaad YM, Hammad A, Fawzy Z et al. C1q rs292001 polymorphism and C1q antibodies in juvenile lupus and their relation to lupus nephritis. Clin Exp Immunol 2015; 182:23-34.
30. Haddon DJ, Diep VK, Price JV, Limb C, Utz PJ, Balboni I. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther 2015; 17:162.
31. Ravelli A, Wisnieski JJ, Ramenghi B, Ballardini G, Zonta L, Martini A. IgG autoantibodies to complement C1q in pediatriconset systemic lupus erythematosus. Clin Exp Rheumatol 1997; 15:215-9.
32. Jesus AA, Silva CA, Carneiro-Sampaio M et al. Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. Ann NY Acad Sci 2009; 1173:235-8.
33. Rudofsky UH. Murine lupus nephritis is accelerated by antiglomerular basement membrane autoantibodies. Clin Exp Immunol 1981; 44:18-23.
34. Li CH, Li YC, Xu PS, Hu X, Wang CY, Zou GL. Clinical significance of anti-glomerular basement membrane antibodies in a cohort of Chinese patients with lupus nephritis. Scand J Rheumatol 2006; 35:201-8.
35. Orjuela A, Suwanichkul A, Canter D et al. High titer antibasement membrane antibodies in a subset of patients with pediatric systemic lupus erythematosus. Am J Nephrol 2015; 41: 241-7.
36. Kanakoudi-Tsakalidou F, Farmaki E, Tzimouli V et al. Simultaneous changes in serum HMGB1 and IFN-a levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options? Lupus 2014; 23:305-12.
37. Bobek D, Grčević D, Kovačić N, Lukić IK, Jeluśić M. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 2014; 12:50.
38. Kozyro I, Korosteleva L, Chernoshej D, Danner D, Sukalo A, Trendelenburg M. Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol 2008; 128:409-1
39. Lu J, Tam LS, Lai FM et al. Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 2011; 34:220-5.